Mid-line destructive syndrome secondary to infection by paracoccidioides sp. A case report
DOI:
https://doi.org/10.17533/udea.iatreia.160Keywords:
Invasive Fungal Diseases , Mycoses , ParacoccidioidomycosisAbstract
Midline destructive disease is a group of severe and destructive inflammatory and tumor diseases of the midface area, among which paracoccidioidomycosis is one of the main etiologies in tropical countries.
Paracoccidioidomycosis is an endemic mycosis caused by fungi of the genus Paracoccidioides. Its blastoconidia form favors hematogenous spread, affecting various tissues such as adrenal glands, eticulo-endothelial tissue, or oral mucosa, where it can manifest as a estructive midline syndrome. We present a case of paracoccidioidomycosis with affection in the oral cavity, which debuted as a chronic midline destructive disease with sever airway compromise that required surgical treatment for the risk of obstruction of the airway.
The patient received systemic treatment with good response.
Downloads
References
(1) Rodríguez G, Sarmiento L, Hernández CA. Leishmaniasis mucosa y otras lesiones destructivas centrofaciales. Biomédica. 1994;14(4):215. DOI 10.7705/biomedica.v14i4.2108.
(2) Sanabria C, Alarcón M, Alarcón I, Jaimes M. Paracoccidioidomicosis A multisystemic disease. Acta Médica Colomb. 2018;43(5):111–4. DOI 10.36104/amc.2018.734.
(3) Bellissimo-Rodrigues F, Machado AA, Martinez R. Paracoccidioidomycosis epidemiological features of a 1,000-cases series from a hyperendemic area on the southeast of Brazil. Am J Trop Med Hyg. 2011 Sep;85(3):546–50. DOI 10.4269/ajtmh.2011.11-0084.
(4) Blotta MH, Mamoni RL, Oliveira SJ, Nouér SA, Papaiordanou PM, Goveia A, et al. Endemic regions of paracoccidioidomycosis in Brazil: a clinical and epidemiologic study of 584 cases in the southeast region. Am J Trop Med Hyg. 1999 Sep;61(3):390–4. DOI 10.4269/ajtmh.1999.61.390.
(5) Torrado E, Castañeda E, de la Hoz F, Restrepo A. Paracoccidioidomicosis: definición de las áreas endémicas de Colombia. Biomédica. 2000;20(4):327–34. DOI 10.7705/biomedica.v20i4.1076.
(6) Calle D, Rosero DS, Orozco LC, Camargo D, Castañeda E, Restrepo A. Paracoccidioidomycosis in Columbia: An ecological study. Epidemiol Infect. 2001;126(2):309–15. DOI 10.1017/S0950268801005052.
(7) Restrepo-Moreno A, Tobon-Orozco AM, Angel GM. Paracoccidioidomycosis. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett`s Principles and practice of Infectious Diseases. 9th ed. Philadelphia, United States: Elsevier; 2019. p. 4108–19.
(8) Restrepo A, Gómez BL, Tobón A. Paracoccidioidomycosis: Latin America’s Own Fungal Disorder. Curr Fungal Infect Rep. 2012;6(4):303–11. DOI 10.1007/s12281-012-0114-x.
(9) Shankar J, Restrepo A, Clemons KV, Stevens DA. Hormones and the resistance of women to paracoccidioidomycosis. Clin Microbiol Rev. 2011 Apr;24(2):296–313. DOI 10.1128/CMR.00062-10.
(10) Franco M, Montenegro MR, Mendes RP, Marques SA, Dillon NL, Mota NG. Paracoccidioidomycosis: a recently proposed classification of its clinical forms. Rev Soc Bras Med Trop. 1987;20(2):129–32. DOI 0.1590/S0037-86821987000200012.
(11) Restrepo A. Morphological aspects of Paracoccidioides brasiliensis in lymph nodes: Implications for the prolonged latency of paracoccidioidomycosis? Med Mycol. 2000;38(4):317–22. DOI 10.1080/mmy.38.4.317.322.
(12) Mendes RP, Cavalcante RS, Marques SA, Marques MEA, Venturini J, Sylvestre TF, Et al. Paracoccidioidomycosis: Current Perspectives from Brazil. Open Microbiol J. 2017 Oct 31;11:224-282. DOI 10.2174/1874285801711010224.
(13) Restrepo A, Tobón AM, Agudelo CA, Ochoa JE, Rosero DS, Osorio ML, et al. Co-existence of integumentary lesions and lung X-ray abnormalities in patients with paracoccidioidomycosis (PCM). Am J Trop Med Hyg. 2008;79(2):159–63. DOI 10.4269/ajtmh.2008.79.159.
(14) Marques SA. Paracoccidioidomicose: Atualização epidemiológica, clínica, diagnóstica e terapêutica. An Bras Dermatol. 2013;88(5):700–11. DOI 10.1590/abd1806-4841.20132463.
(15) Restrepo A, Benard G, de Castro CC, Agudelo CA, Tobón AM. Pulmonary paracoccidioidomycosis. Semin Respir Crit Care Med. 2008 Apr;29(2):182–97. DOI 10.1055/s-2008-1063857.
(16) Paniago AMM, Aguiar JIA, Aguiar ES, Cunha RV da, Pereira GR de OL, Londero AT, et al. Paracoccidioidomicose: estudo clínico e epidemiológico de 422 casos observados no Estado de Mato Grosso do Sul. Rev Soc Bras Med Trop. 2003;36(4):455–9. DOI 10.1590/S0037-86822003000400004.
(17) Campos MVS, Penna GO, De Castro CN, De Moraes MAP, Ferreira MS, Santos JB. Paracoccidioidomicose no Hospital Universitário de Brasília. Rev Soc Bras Med Trop. 2008;41(2):169–72. DOI 10.1590/S0037-86822008000200007.
(18) Abreu e Silva MÀ de, Salum FG, Figueiredo MA, Cherubini K. Important aspects of oral paracoccidioidomycosis--a literature review. Mycoses. 2013 May;56(3):189–99. DOI 10.1111/myc.12017.
(19) Fortes MRP, Miot HA, Kurokawa CS, Marques MEA, Marques SA. Immunology of paracoccidioidomycosis. An Bras Dermatol. 2011;86(3):516–25. DOI 10.1590/S0365-05962011000300014.
(20) Teles FRR, Martins ML. Laboratorial diagnosis of paracoccidioidomycosis and new insights for the future of fungal diagnosis. Talanta. 2011;85(5):2254–64. DOI 10.1016/j.talanta.2011.07.099.
(21) Endo S, Komori T, Ricci G, Sano A, Yokoyama K, Ohori A, et al. Detection of gp43 of Paracoccidioides brasiliensis by the loop-mediated isothermal amplification (LAMP) method. FEMS Microbiol Lett. 2004;234(1):93–7. DOI 10.1111/j.1574-6968.2004.tb09518.x.
(22) Da Silva SHM, De Mattos Grosso D, Lopes JD, Colombo AL, Blotta MHSL, Queiroz-Telles F, et al. Detection of Paracoccidioides brasiliensis gp70 circulating antigen and follow-up of patients undergoing antimycotic therapy. J Clin Microbiol. 2004;42(10):4480–6. DOI 10.1128/JCM.42.10.4480-4486.2004.
(23) Díez S, Gómez BL, McEwen JG, Restrepo A, Hay RJ, Hamilton AJ. Combined use of Paracoccidioides brasiliensis recombinant 27-kilodalton and purified 87-kilodalton antigens in an enzyme-linked immunosorbent assay for serodiagnosis of paracoccidioidomycosis. J Clin Microbiol. 2003;41(4):1536–42. DOI 10.1128/JCM.41.4.1536-1542.2003.
(24) Colombo TE, Soares MMCN, D’Ávilla SCGP, Nogueira MCL, de Almeida MTG. Identification of fungal diseases at necropsy. Pathol - Res Pract. 2012;208(9):549–52. DOI 10.1016/j.prp.2012.06.004.
(25) Cock AM, Cano LE, Vélez D, Aristizábal BH, Trujillo J, Restrepo A. Fibrotic sequelae in pulmonary paracoccidioidomycosis: Histopathological aspects in BALB/c mice infected with viable and non-viable Paracoccidioides brasiliensis propagules. Rev Inst Med Trop Sao Paulo. 2000;42(2):59–66. DOI 10.1590/S0036-46652000000200001.
(26) Shikanai-Yasuda MA, Benard G, Higaki Y, Del Negro GMB, Hoo S, Vaccari EH, et al. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis.
Med Mycol. 2002 Aug;40(4):411–7. DOI 10.1080/mmy.40.4.411.417.
(27) Shikanai-Yasuda MA, Telles Filho F de Q, Mendes RP, Colombo AL, Moretti ML. [Guidelines in paracoccidioidomycosis]. Rev Soc Bras Med Trop. 2006;39(3):297–310. DOI 10.1590/S0037-86822006000300017.
(28) Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A, Shikanai-Yasuda MA. An openlabel comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2007 Dec;45(11):1462–9. DOI 10.1086/522973.
(29) Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, et al. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2016 Aug;63(3):356–62. DOI /10.1093/cid/ciw305.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Iatreia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
